PAG
PCRX icon

Private Advisor Group’s Pacira BioSciences PCRX Stock Holding History

Private Advisor Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,786
Closed -$94K – 2885
2020
Q2 		$94K Buy
+1,786
New +$74.6K ﹤0.01% 1738
2017
Q2 		– Sell
-11,804
Closed -$92K – 1447
2017
Q1 		$92K Buy
+11,804
New +$510K ﹤0.01% 1364
2015
Q2 		– Sell
-2,588
Closed -$230K – 1092
2015
Q1 		$230K Buy
2,588
+232
+10% +$23.5K 0.01% 829
2014
Q4 		$209K Buy
2,356
+161
+7% +$15.2K 0.01% 861
2014
Q3 		$213K Sell
2,195
-200
-8% -$19.5K 0.01% 827
2014
Q2 		$220K Buy
+2,395
New +$182K 0.02% 758

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Private Advisor Group's PCRX Position: Q3 2020 in Review

Private Advisor Group sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 1,786 shares — an estimated $94K sold.

Private Advisor Group first reported a position in PCRX in Q2 2014 and held it in 6 quarters. The position peaked at $230K in Q1 2015. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

  • Private Advisor Group reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 1,786 Pacira BioSciences shares in Q3 2020, an estimated $94K.
  • Private Advisor Group first reported a position in Pacira BioSciences in Q2 2014 and held it in 6 quarters.
  • Private Advisor Group's Pacira BioSciences position peaked at $230K in Q1 2015.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.